Citi removed Boston Scientific (BSX) from the firm’s Focus List while keeping a Buy rating on the shares with a $130 price target The removal follows the company reiterating its long-term outlook.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific: Diversified Growth Engines and Strong Execution Underpin Reiterated Buy Rating
- Reaffirming Buy on Boston Scientific: Strategic Pelvic Health Expansion and High-Growth Valencia Technologies Acquisition Support Upside Potential
- 3 Best ETFs to Invest In, According to AI Analyst, 01/12/2026
- Boston Scientific to acquire Valencia Technologies, terms not disclosed
- Boston Scientific price target lowered to $112 from $124 at Goldman Sachs